The deadline to submit comments to the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) as it responds to the Food and Drug Administration’s (FDA) document on patient-focused drug development is today.
According to an email, the document is the second in a series of draft guidance documents from the FDA. ISPOR responded to the first document in September last year.
To learn more, click here.
